146 reports of this reaction
4.0% of all CISATRACURIUM BESYLATE reports
#2 most reported adverse reaction
HYPOTENSION is the #2 most commonly reported adverse reaction for CISATRACURIUM BESYLATE, manufactured by Fresenius Kabi USA, LLC. There are 146 FDA adverse event reports linking CISATRACURIUM BESYLATE to HYPOTENSION. This represents approximately 4.0% of all 3,661 adverse event reports for this drug.
Patients taking CISATRACURIUM BESYLATE who experience hypotension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOTENSION is moderately reported among CISATRACURIUM BESYLATE users, representing a notable but not dominant share of adverse events.
In addition to hypotension, the following adverse reactions have been reported for CISATRACURIUM BESYLATE:
The following drugs have also been linked to hypotension in FDA adverse event reports:
HYPOTENSION has been reported as an adverse event in 146 FDA reports for CISATRACURIUM BESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOTENSION accounts for approximately 4.0% of all adverse event reports for CISATRACURIUM BESYLATE, making it one of the most commonly reported side effect.
If you experience hypotension while taking CISATRACURIUM BESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.